about
Identification of 5-Iodotubercidin as a genotoxic drug with anti-cancer potentialMir-655 up-regulation suppresses cell invasion by targeting pituitary tumor-transforming gene-1 in esophageal squamous cell carcinoma.Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells.let-7b and miR-126 are down-regulated in tumor tissue and correlate with microvessel density and survival outcomes in non--small--cell lung cancer.Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer.TRPM8 ion channels differentially modulate proliferation and cell cycle distribution of normal and cancer prostate cellsAntitumor effects of a dual cancer-specific oncolytic adenovirus on colorectal cancer in vitro and in vivoTargeted expression of tumor necrosis factor-related apoptosis-inducing ligand TRAIL in skin protects mice against chemical carcinogenesis.Senescence-secreted factors activate Myc and sensitize pretransformed cells to TRAIL-induced apoptosis.Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway.Acquired resistance to drugs targeting receptor tyrosine kinasesEffects of cucurbitacins on cell morphology are associated with sensitization of renal carcinoma cells to TRAIL-induced apoptosis.Virotherapy, gene transfer and immunostimulatory monoclonal antibodies.An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosisCancer stem cells and chemoresistance: The smartest survives the raidTranscriptional repression of AIB1 by FoxG1 leads to apoptosis in breast cancer cellsSalmonella typhimurium mediated delivery of Apoptin in human laryngeal cancer.Anti-tumor activity of SL4 against breast cancer cells: induction of G2/M arrest through modulation of the MAPK-dependent p21 signaling pathway.Network quantification of EGFR signaling unveils potential for targeted combination therapy.Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia.P-glycoprotein-dependent resistance of cancer cells toward the extrinsic TRAIL apoptosis signaling pathway.Naturally occurring, tumor-specific, therapeutic proteins.New frontiers in promoting tumour cell death: targeting apoptosis, necroptosis and autophagy.Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategiesMechanisms of tumor cell resistance to the current targeted-therapy agents.Epigenetic and expression analysis of TRAIL-R2 and BCL2: on the TRAIL to knowledge of apoptosis in ovarian tumors.Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species.PTTG1 promotes migration and invasion of human non-small cell lung cancer cells and is modulated by miR-186.Apoptin selectively induces the apoptosis of tumor cells by suppressing the transcription of HSP70.Development of isoxazoline-containing peptidomimetics as dual αvβ3 and α5β1 integrin ligands.Thioether analogues of disulfide-bridged cyclic peptides targeting death receptor 5: conformational analysis, dimerisation and consequences for receptor activation.Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels.Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells.Structure-based approach to the design of BakBH3 mimetic peptides with increased helical propensity.Photosensitizer (PS)/polyhedral oligomeric silsesquioxane (POSS)-crosslinked nanohybrids for enhanced imaging-guided photodynamic cancer therapy.Sensitization of glioma cells by X-linked inhibitor of apoptosis protein knockdown.Acquired Resistance to Drugs Targeting Tyrosine Kinases.An Innovative Cell Microincubator for Drug Discovery Based on 3D Silicon Structures
P2860
Q28487720-85BA3A0A-A315-4A32-BB1E-EB492BE52D2BQ33643722-07903E9E-3678-491B-B5B0-2F8B59492F57Q33695003-76660085-4C54-49B1-95C4-7320B91140E4Q34429485-E55BECF5-F0A9-46F1-AD2A-6E15055A7E72Q34483455-B443C01F-1410-4929-A1CD-50F1771FBFF4Q34517285-230AEBF9-36BF-4129-8679-AD9F4BB543ECQ34795642-D20DAAB8-51A0-42A7-92E4-24AC68AB9FF9Q34809370-2105F8E7-93CF-48A4-9E16-813656468B20Q35080496-321DE6BB-BFCA-4866-B974-F12EC147B43DQ35419466-B18E3813-1A3B-42D4-8FF2-902EF903EE14Q35823437-03AAFBE8-F668-486A-AED6-2F6B503D3CA5Q35938641-1DB83F9D-F852-4316-A5EC-1DEEF04B9690Q36456487-1E7DDB5C-6FED-4FDA-9456-34571C5B1F09Q36695591-7C28D847-CCF9-49DF-8787-73A21BD9B152Q36730432-1D731270-7291-49AF-B44F-F6E5E02E0CDDQ36998051-46C5C519-3EF2-40DE-88B3-26F383605C54Q37249330-F765B24B-BE84-4155-ADD9-04E86039DDD7Q37397423-BE64EB63-6927-4D71-BA0B-E21E01F0BE9DQ37660498-8F9C8559-60F8-418C-B78D-9321C9E36E71Q37688465-D57DCBD7-BEF3-45B1-B955-43FCDDB4DB9EQ37723845-D442E157-8F5B-4BEB-839E-388680326CD3Q37869260-0A862AC3-0748-406F-A374-F98ED664D122Q37981834-34445DC6-4D82-4AA7-B6AD-AEC2B77CB84CQ38139255-7C46C9A4-0283-4FFF-9FD8-7F859BCBB576Q38828353-27EA3583-BB15-489C-94C9-3465F85A5037Q39066974-921F667D-201A-465C-87C4-E74903ABBAA3Q39099843-C9F261E9-93D5-4B20-A583-350FB0B607CEQ39152387-C382002A-CD87-48C8-BF9C-7A62196C7B31Q39239188-A7BDF551-F3B3-4AC5-992B-CBABDFE54E0CQ39466935-5993367E-33E7-47DB-8C61-3E36A6C83451Q41714576-2D8DE7F7-D1AE-4EE5-8D38-F41AC4B56191Q41778655-736A42C2-CE29-41F8-B7F3-D9C416060B41Q42358231-A43DE92A-0AF1-4B39-B509-ADBA04E210B2Q45833697-165B41AA-B5DB-4123-817A-8D0EC03986FFQ47949536-CE7BC179-67E1-4BE6-9FE5-A07DFDF45B81Q53159288-BB8F6846-8008-4DAD-895C-41631B4BAAC6Q53701267-98F23B73-5296-48FF-A116-DF4634F79E95Q59128698-95D597B5-3495-461A-9F0E-E80F8963EEC7
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Towards novel paradigms for cancer therapy.
@en
Towards novel paradigms for cancer therapy.
@nl
type
label
Towards novel paradigms for cancer therapy.
@en
Towards novel paradigms for cancer therapy.
@nl
prefLabel
Towards novel paradigms for cancer therapy.
@en
Towards novel paradigms for cancer therapy.
@nl
P2860
P50
P356
P1433
P1476
Towards novel paradigms for cancer therapy
@en
P2093
P2860
P2888
P356
10.1038/ONC.2010.460
P407
P577
2010-10-11T00:00:00Z